Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like Kitov Pharma Surges as Lead Drug Hits Goals in Phase III Test October 26, 2017 Cambridge Biotech Enumeral Biomedical Has Cash to Fund Its Operations Only Into Next Month May 29, 2017 Catalent Reports Second Quarter Fiscal Year 2017 Results February 6, 2017
Cambridge Biotech Enumeral Biomedical Has Cash to Fund Its Operations Only Into Next Month May 29, 2017